$FUSE

Fusemachines Reports Revenue Growth and Operating Loss Improvements in Q3 2026 Results

Fusemachines Inc. (FUSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fusemachines Reports Revenue Growth and Operating Loss Improvements in Q3 2026 Results Adjusted EBITDA (non-GAAP) improves 39.2%, revenue grows 2.8%, and GAAP operating loss improves 14.0% quarter-over-quarter NEW YORK, November 3, 2026 — Fusemachines Inc. (Nasdaq: F

Original reporting
Published Nov 3, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$FUSE
Bullish
medium confidence
Mentioned
$FUSE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FUSEBullishMed
01

Why it matters

Investors get fresh quarterly datapoints on revenue, GAAP operating loss, and non-GAAP Adjusted EBITDA, alongside explicit going-concern risk language that can cap multiple expansion.

02

Market read

A company-specific earnings-style update with measurable sequential improvements, but risk disclosures (going concern, negative operating cash flow) keep the setup mixed.

03

What to watch

Forward purchase agreement transactions drove equity improvement, which may not translate into sustainable operating cash flow; going-concern language can dominate valuation despite EBITDA progress.

Relevance 7/10Novelty 8/10Timing: after-hours/filing day, following the Q3 2026 results release

Background

SEC Form 8-K Item 2.02 furnished Fusemachines’ Q3 2026 results, highlighting sequential revenue growth and expense reductions.

Company-level read

Ticker impact

$FUSEBullishMedium confidence
Context

Fusemachines reports Q3 2026 revenue up 2.8% to $1.85M and GAAP operating loss improving 14% to $2.3M, plus Adjusted EBITDA loss narrowing 39.2%.

Expected impact

Likely near-term support as investors price in cost-reduction progress, tempered by ongoing cash burn and going-concern language.

Evidence & confidence

Sequential expense declines and improved losses are concrete, but the filing emphasizes continued stockholders’ deficit, negative operating cash flow, and substantial doubt about going concern.

Market effects

Adds datapoint on cost discipline among enterprise AI services providers, but no clear sector-wide read-through from a single microcap print.

Primarily US-listed microcap sentiment; limited broader regional impact.

Limited global relevance beyond investor perception of AI services profitability trends.

Counterpoint

Revenue growth is small and the GAAP net loss remains large, with a sizable non-cash derivative fair-value charge, so the quality of improvement may be limited.

Key entities

  • Fusemachines Inc.

    Nasdaq-listed enterprise AI products and services provider reporting Q3 2026 financial results on Form 8-K.

  • Sameer Maskey

    Founder and CEO quoted on cost-reduction progress and operating efficiency improvements.

Related articles

$FUSEMedAI 8/10

Fusemachines Closes Up to $10.66 Million Investment at $4.20 per Share for Growth Capital from Existing Investor Meteora Capital

Fusemachines Inc. (NASDAQ: FUSE) said existing investor Meteora Capital added $2.5 million via a convertible note with a fixed $4.20 per share conversion price, plus 2.05 million warrants exercisable at $4.20. If all warrants are exercised, Fusemachines could receive up to $8.61 million more, totaling $10.66 million. Proceeds will fund its Agentic AI platform development and commercialization.

$MDGLMed

Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%

Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.

$FDXHighAI 8/10

FedEx Network 2.0 headed to Los Angeles, other markets post-holidays

FedEx has completed its Network 2.0 overhaul in several U.S. markets, with 65% of eligible volume now flowing through optimized stations. The company plans to expand the initiative to Los Angeles and other markets post-holidays, aiming for $2 billion in cost savings by 2024. FedEx also reported higher costs due to labor and fuel prices, but expects 12% full-year revenue growth.

$FDXHighAI 8/10

FedEx CEO is seeing a shift in its customer base

FedEx reported Q3 revenue of $22.9B (+12%) and adjusted EPS of $3.74 (+28%), driven by a shift to higher-margin customers. The company is focusing on business-to-business, healthcare, and data center logistics, with international operations showing strong growth. FedEx plans to close 475 locations by 2027, aiming for $2B in savings. Full-year adjusted EPS guidance was raised to $18.00-$18.60.